Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Century Therapeutics reported Q2 2026 results with $0 revenue and a net loss of $34.6M (EPS $(0.17)), compared to a $32.5M loss in the prior year. The company advanced IND-enabling studies for CNTY-813, targeting an IND filing in Q4 2026. Operational efficiencies were achieved through cost realignment, while cash reserves are projected to sustain operations through Q1 2029.
Century Therapeutics, Inc. reported results for the quarter ended 2Q 2026, posting revenue of $0 and a net loss of $34.6M, or diluted EPS of $(0.17), compared with a net loss of $32.5M and diluted EPS of $(0.38) in the year‑ago quarter.
Financial Highlights
- Revenue was $0 for Q2 2026, versus $0 for Q2 2025 (BMS collaboration revenue of $109.2M was recognized in 1H 2025, not in Q2 2025).
- Net income was $(34.6) M for Q2 2026, compared with $(32.5) M in Q2 2025 (loss increased (6.3%) year over year).
- Diluted EPS was $(0.17) for Q2 2026, versus $(0.38) for Q2 2025.
Business Highlights
- Pipeline progress: IND‑enabling studies advancing for lead CNTY‑813 islet therapy; IND planned for Q4 2026 with initial clinical data anticipated in H2 2027.
- Platform & differentiation: Continued development of Allo‑Evasion™ v5.0 and iPSC‑derived islet, CAR‑iT (CNTY‑308) and iNK programs focused on scalable, off‑the‑shelf manufacturing.
- Operational milestones: Established a Phase 1 clinical manufacturing process for CNTY‑813 across three independent batches and presented supporting preclinical efficacy and immune‑evasion data.
- Cost realignment: R&D and G&A headcount and facility allocations reduced through portfolio prioritization to lower near‑term operating spend and refocus programs.
- Liquidity: Cash and investments are expected to support operations into Q1 2029, enabling ongoing IND‑enabling work and manufacturing scale‑up.
Original SEC Filing: Century Therapeutics, Inc. [ IPSC ] - 10-Q - Aug. 12, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.